{"id":"zoster-vaccine-recombinant-adjuvanted","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site erythema"},{"rate":"40-50","effect":"Injection site pain"},{"rate":"30-40","effect":"Injection site swelling"},{"rate":"30-40","effect":"Myalgia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"20-30","effect":"Headache"},{"rate":"10-20","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL1201718","moleculeType":"Enzyme"},"_dailymed":{"setId":"c46e8702-5680-462b-a093-0c7720f77020","title":"SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED) INJECTION, SOLUTION [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant VZV glycoprotein E (gE) combined with an adjuvant system (AS01B) that enhances immune response. The adjuvant potentiates both humoral and cellular immunity, providing durable protection against reactivation of latent VZV infection that causes herpes zoster in older adults and immunocompromised individuals.","oneSentence":"This recombinant zoster vaccine with adjuvant stimulates the immune system to generate protective antibodies and cell-mediated immunity against varicella-zoster virus (VZV) to prevent herpes zoster (shingles).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:59:22.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"},{"name":"Prevention of herpes zoster in immunocompromised adults"}]},"trialDetails":[{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT05580458","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-13","conditions":"Herpes Zoster","enrollment":225},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT07311148","phase":"PHASE2","title":"A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-23","conditions":"Herpes Zoster (HZ), Shingles, VZV","enrollment":840},{"nctId":"NCT06874842","phase":"PHASE1","title":"Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older","status":"RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-03-13","conditions":"Herpes Zoster (HZ)","enrollment":92},{"nctId":"NCT06262776","phase":"NA","title":"Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Central Adelaide Local Health Network Incorporated","startDate":"2024-03-20","conditions":"Immunosuppression, Vaccine Response Impaired","enrollment":120},{"nctId":"NCT05991427","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-11-07","conditions":"Herpes Zoster","enrollment":65},{"nctId":"NCT06654700","phase":"PHASE3","title":"Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-12-09","conditions":"Herpes Zoster","enrollment":1200},{"nctId":"NCT05636436","phase":"PHASE1","title":"Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2022-12-07","conditions":"Herpes Zoster","enrollment":132},{"nctId":"NCT05856084","phase":"PHASE2","title":"Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-05-07","conditions":"Herpes Zoster","enrollment":924},{"nctId":"NCT06447779","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-07-13","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT06334861","phase":"","title":"Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-06-23","conditions":"Herpes Zoster","enrollment":178},{"nctId":"NCT06224270","phase":"PHASE4","title":"Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2024-10","conditions":"Inflammatory Bowel Diseases, IBD","enrollment":""},{"nctId":"NCT04047979","phase":"PHASE2","title":"Systems Biology of Zoster Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-14","conditions":"Zoster, Zoster Varicella, Shingles","enrollment":38},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT03771157","phase":"EARLY_PHASE1","title":"Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-02-01","conditions":"Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)","enrollment":33},{"nctId":"NCT04523246","phase":"EARLY_PHASE1","title":"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2020-09-01","conditions":"Herpes Zoster, Allergy and Immunology, Corona Virus Infection","enrollment":217},{"nctId":"NCT03702231","phase":"PHASE2","title":"Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL)","enrollment":116},{"nctId":"NCT05750017","phase":"PHASE1","title":"A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-03-23","conditions":"Herpes Zoster, Vaccine-Preventable Diseases","enrollment":66},{"nctId":"NCT05718037","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2023-08-01","conditions":"Herpes Zoster","enrollment":40},{"nctId":"NCT05705180","phase":"","title":"The Influence of Trained Immunity in COVID-19 Vaccinated Individuals","status":"UNKNOWN","sponsor":"Wuerzburg University Hospital","startDate":"2022-12-01","conditions":"Zoster Varicella, Vaccination; Infection","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Shingrix","SHINGRIX"],"phase":"marketed","status":"active","brandName":"Zoster Vaccine Recombinant, Adjuvanted","genericName":"Zoster Vaccine Recombinant, Adjuvanted","companyName":"Wuhan BravoVax Co., Ltd.","companyId":"wuhan-bravovax-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This recombinant zoster vaccine with adjuvant stimulates the immune system to generate protective antibodies and cell-mediated immunity against varicella-zoster virus (VZV) to prevent herpes zoster (shingles). Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}